[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 103, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1130500, "exercisedValue": 0, "unexercisedValue": 107640504}, {"maxAge": 1, "name": "Dr. Thomas  Diraimondo Ph.D.", "age": 38, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 630000, "exercisedValue": 0, "unexercisedValue": 28001912}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 59, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 727500, "exercisedValue": 0, "unexercisedValue": 7877545}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 35, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1989, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 55, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Janeen  Doyle", "title": "Chief Corporate & Business Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 40, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachariah  McIver D.O., Ph.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 23.94, "open": 24.04, "dayLow": 23.85, "dayHigh": 24.75, "regularMarketPreviousClose": 23.94, "regularMarketOpen": 24.04, "regularMarketDayLow": 23.85, "regularMarketDayHigh": 24.75, "payoutRatio": 0.0, "beta": 2.837, "forwardPE": -14.987499, "volume": 408989, "regularMarketVolume": 408989, "averageVolume": 763301, "averageVolume10days": 525860, "averageDailyVolume10Day": 525860, "bid": 23.94, "ask": 24.09, "bidSize": 3, "askSize": 1, "marketCap": 1441051648, "fiftyTwoWeekLow": 21.971, "fiftyTwoWeekHigh": 71.71, "priceToSalesTrailing12Months": 3282.578, "fiftyDayAverage": 24.5119, "twoHundredDayAverage": 33.7877, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 467231488, "profitMargins": 0.0, "floatShares": 44967087, "sharesOutstanding": 60093900, "sharesShort": 8075479, "sharesShortPriorMonth": 9654389, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.1344, "heldPercentInsiders": 0.0659, "heldPercentInstitutions": 1.10004, "shortRatio": 9.06, "shortPercentOfFloat": 0.19309999, "impliedSharesOutstanding": 60093900, "bookValue": 16.704, "priceToBook": 1.4355842, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -105641000, "trailingEps": -1.81, "forwardEps": -1.6, "enterpriseToRevenue": 1064.309, "enterpriseToEbitda": -3.272, "52WeekChange": -0.42700118, "SandP52WeekChange": 0.18469036, "quoteType": "EQUITY", "currentPrice": 23.98, "targetHighPrice": 200.0, "targetLowPrice": 25.0, "targetMeanPrice": 81.71429, "targetMedianPrice": 74.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 14, "totalCash": 996011008, "totalCashPerShare": 16.574, "ebitda": -142796992, "totalDebt": 22190000, "quickRatio": 46.854, "currentRatio": 47.035, "totalRevenue": 439000, "debtToEquity": 2.24, "revenuePerShare": 0.007, "returnOnAssets": -0.10507, "returnOnEquity": -0.12819, "grossProfits": -67949000, "freeCashflow": -30383376, "operatingCashflow": -59793000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -330.0205, "financialCurrency": "USD", "symbol": "JANX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Janux Therapeutics, Inc.", "regularMarketChangePercent": 0.16708, "regularMarketPrice": 23.98, "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 763301, "fiftyTwoWeekLowChange": 2.0089989, "fiftyTwoWeekLowChangePercent": 0.09143866, "fiftyTwoWeekRange": "21.971 - 71.71", "fiftyTwoWeekHighChange": -47.73, "fiftyTwoWeekHighChangePercent": -0.66559756, "fiftyTwoWeekChangePercent": -42.70012, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.81, "epsForward": -1.6, "epsCurrentYear": -2.20956, "priceEpsCurrentYear": -10.852839, "fiftyDayAverageChange": -0.5319004, "fiftyDayAverageChangePercent": -0.02169968, "twoHundredDayAverageChange": -9.807701, "twoHundredDayAverageChangePercent": -0.2902743, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-11", "averageAnalystRating": "1.2 - Strong Buy", "corporateActions": [], "postMarketTime": 1757104920, "regularMarketTime": 1757102401, "exchange": "NGM", "messageBoardId": "finmb_676965261", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Janux Therapeutics, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623418200000, "postMarketChangePercent": 0.0, "postMarketPrice": 23.98, "postMarketChange": 0.0, "regularMarketChange": 0.039999, "regularMarketDayRange": "23.85 - 24.75", "cryptoTradeable": false, "displayName": "Janux Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-06"}]